Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00077675
Status:
COMPLETED
Last Update Posted:
2019-01-16
First Post:
2004-02-10
Brief Title:
Phase 2 Trial of TD-6424 Telavancin Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections Gram Positive cSSSI
Sponsor:
Cumberland Pharmaceuticals
Organization:
Cumberland Pharmaceuticals
Study Overview
Official Title:
A Phase 2 Randomized Double-Blind Multinational Trial of Intravenous Telavancin Versus Standard Therapy for Treatment of Complicated Gram-Positive Skin and Skin Structure Infections Gram Positive cSSSI
Status:
COMPLETED
Status Verified Date:
2019-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FAST2
Brief Summary:
Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world This study will measure how well TD-6424 Telavancin can control infections and whether the drug is safe to give to patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None